Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lisa G. Patel"'
Autor:
Calvin J. Cohen, Linda Yau, Anthony LaMarca, Paul Wannamaker, Benjamin Young, Mary Beth Wire, Edwin DeJesus, Mark S. Shaefer, Lisa G. Patel, Cindy Vavro
Publikováno v:
HIV Clinical Trials. 11:239-247
ritonavir (RTV) effectively boosts most protease inhibitors but is associated with significant dose-dependent adverse events (AEs). In an effort to better manage toxicities through a reduced dose of RTV, this study compared fosamprenavir (FPV) booste
Autor:
Kathleen E, Squires, Benjamin, Young, Edwin, Dejesus, Nicholaos, Bellos, Daniel, Murphy, Henry H, Zhao, Lisa G, Patel, Lisa L, Ross, Paul G, Wannamaker, Mark S, Shaefer, B, Young
Publikováno v:
AIDS. 24:2019-2027
Background Treatment simplification strategies involving induction with a ritonavir (RTV)-boosted (/r) protease inhibitor regimen followed by simplification (without RTV) are appealing because they may offer sustained virologic suppression while mini
Autor:
Philip Lackey, Joseph C. Gathe, Edwin DeJesus, Linda Yau, Christine Katlama, Mark S. Shaefer, Vicente Estrada, Jane Yeo, Benjamin Young, Paul Wannamaker, Schlomo Staszewski, Patrick Yeni, Denise H. Sutherland-Phillips, Joseph J. Eron, Lisa G. Patel, Cindy Vavro
Publikováno v:
The Lancet. 368:476-482
Summary Background Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety to lopinavir-ritonavir when each is combined with two nucleoside revers
Autor:
Roderick G. Davis, Emily A. Hull-Ryde, Jon L. Collins, Jennifer L. Shenk, James M. Lenhard, Thomas G. Consler, Julie B. Stimmel, Timothy M. Willson, Lisa M. Leesnitzer, Steven G. Blanchard, Jeff E. Cobb, Christina Therapontos, Lisa G. Patel, Derek J. Parks, Kelli D. Plunket, Randy K. Bledsoe
Publikováno v:
Biochemistry. 41:6640-6650
In the course of a high throughput screen to search for ligands of peroxisome proliferator activated receptor-gamma (PPARgamma), we identified GW9662 using a competition binding assay against the human ligand binding domain. GW9662 had nanomolar IC(5
Autor:
Aries Study Team, Lisa L. Ross, Nicholas Bellos, Lisa G. Patel, Denise H. Sutherland-Phillips, Benjamin Young, Daniel Murphy, Kathleen Squires, Edwin DeJesus, Henry H. Zhao, Paul Wannamaker, Mark S. Shaefer
Publikováno v:
HIV clinical trials. 11(2)
The ARIES study assessed safety and efficacy of an induction regimen with atazanavir/ritonavir (ATV/RTV) + abacavir/lamivudine (ABC/3TC) followed by simplification to ATV + ABC/3TC in antiretroviral-naïve patients.This report includes a noncomparati
Publikováno v:
AIDS patient care and STDs. 23(11)
Screening for HLA-B 5701 reduces the risk of developing an abacavir hypersensitivity reaction (ABC HSR) and is recommended in all patients before initiating highly active antiretroviral therapy (HAART) with abacavir. Between September 2007 and March
Autor:
Watson, Maria E., Patel, Lisa G., Ha, Belinda, Wannamaker, Paul, Cuffe, Robert, Shaefer, Mark
Publikováno v:
AIDS Patient Care & STDs; Nov2009, Vol. 23 Issue 11, p957-963, 7p, 3 Charts